Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback